Unlike propofol, sevoflurane exposure resulted in bigger tumour size, shorter survival time (assessed with the clinical endpoints, including body weight loss > 20% and tumour volume > 70 mm3), higher HGF, HIF1α, IL1β and TNFα expressions, and lower E-cadherin and TIMP-2 expressions. This evidence concerns the gene CDH1 and neoplasm.